Monoamine oxidase inhibitor
 ;templatestyles src="Infobox drug/styles.css"/ ;
SU-11739 (other developmental code names AGN-1133, J-508; also known as "N"-methyl-"N"-propargyl-1-aminoindane) is an experimental monoamine oxidase inhibitor (MAOI) that was never marketed.
It is a dual or non-selective irreversible monoamine oxidase A (MAO-A) and monoamine oxidase B (MAO-B) inhibitor, with preference for inhibition of MAO-B over MAO-A. It is less selective for MAO-B inhibition than AGN-1135 (racemic rasagiline) or rasagiline. In addition to its MAOI activity, SU-11739 has been reported to have strong activity as a catecholamine releasing agent. Similarly to rasagiline, but unlike selegiline and desmethylselegiline, SU-11739 is not a monoaminergic activity enhancer (MAE).
The drug is the racemic "N"-methylated analogue of rasagiline. It is also a ring-cyclized analogue of pargyline with about 20times the MAOI potency of pargyline.
SU-11739 was discovered before rasagiline and was patented in 1965.
References.
 ;templatestyles src="Reflist/styles.css" / ;